

Academic Accomplishments 2017 (Inova authors bolded)

ORIGINAL RESEARCH MANUSCRIPTS

1. **Nathan SD**, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzk DR, Daigl M, Kirchgaessler K, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Effect of Pirfenidone on Mortality: Pooled and Meta Analyses of Three Phase 3 IPF Clinical Trials. *Lancet Respir Med.* 2017 Jan;5(1):33-41.
2. **Nargues A. Weir**, Rehan Saiyed, Shoaib Alam, Anna Conrey, Himanshu D. Desai, M. Patricia George, Jennifer H. Keeley, Elizabeth S. Klings, Alem Mehari, James G. Taylor, Caterina P. Minniti, Gregory J. Kato. Prostacyclin-analog therapy in sickle cell pulmonary hypertension. *Haematologica* January 2017 : haematol.2015.131227; doi:10.3324/haematol.2015.131227
3. C Pittman, M M Hsieh, W Coles, J F Tisdale, **N A Weir** and C D Fitzhugh Reversal of pre-capillary pulmonary hypertension in a patient with sickle cell anemia who underwent haploidentical peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 2017 52(4):641-642.
4. Fisher M, Maher T, **Nathan SD**, Hill C, Marshall J, Dejonckheere F, Thuresson PO. Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. *J Manag Care Spec Pharm.* 2017;23(3-b):S17-S24
5. Jose A, **King C, Shlobin OA, Kiernan J, Cossa N, Nathan SD.** Ventricular diastolic pressure ratio as a marker of treatment response in pulmonary arterial hypertension. *Chest* 2017; 152(5):980-989
6. **King CS, Franco-Palacios D,** Valentine V, **Shlobin OA, Brown AW, Singh R, Nathan SD.** Early Post-Operative Management After Lung Transplantation: Results of an International Survey. *Clin Transplant.* 2017 Jul;31(7). doi: 10.1111/ctr.12985. Epub 2017 May 29
7. Kaler M, Barochia AV, **Weir NA,** Cuento RA, Stylianou M, Roth MJ, Filie A, **Vaughey EC, Nathan SD,** Levine SJ. A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of the PPAR-g Agonist, Pioglitazone, for Severe Asthma. *J Allergy Clin Immunol.* 2017 Jun 15. pii: S0091-6749(17)30989-2. doi: 10.1016/j.jaci.2017.05.033.

REVIEWS

1. **Shlobin OA, Brown AW, Nathan SD.** Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. *Chest.* 2017;151(1):204-214.
2. **King CS, Nathan SD.** Idiopathic Pulmonary Fibrosis: Impact and Optimal Management of Comorbidities. *Lancet Respir Med.* 2017 Jan;5(1):72-84.
3. **Nathan SD,** Behr J, Cottin V, Collard HR, Hoepfer MM, Martinez FJ, Wells AU. Idiopathic interstitial pneumonia pulmonary hypertension: A target for therapy? *Respiratory Medicine* 122 (2017): S10-S13.
4. John H. Newman, Stuart Rich, Steven H. Abman, John H. Alexander, John Barnard, Gerald J. Beck, Raymond L. Benza, Todd M. Bull, Stephen Y. Chan, Hyung J. Chun, Declan Doogan, Jocelyn Dupuis, Scott S. Emerson, Serpil C. Erzurum, Robert P. Frantz, Mark Geraci, Hunter Gillies, Mark Gladwin, Michael P. Gray, Anna Hemnes, Roy S. Herbst, Adrian F. Hernandez, Nicholas S. Hill, Evelyn M. Horn, Kendall Hunter, Zhi-Cheng Jing, Roger Johns, Sanjay Kaul, Steven Kawut, Tim Lahm, Jane A. Leopold, Greg D. Lewis, Stephen C. Mathai, Vallerie V. McLaughlin, Evangelos D. Michelakis, **Steven D. Nathan,** William Nichols, Grier Page, Marlene Rabinovitch, Jonathan Rich, Franz Rischard, Sharon Rounds, Sanjiv J. Shah, Victor F. Tapson, Naomi Lowy, Norman Stockbridge, Gail Weinmann, Lei Xiao. Enhancing Treatments for Pulmonary Vascular Diseases (PVD) Through Precision Medicine. A Joint NHLBI-CMREF

Workshop Report. Am J Respir Crit Care Med. DOI: 10.1164/rccm.201701-0150WS PubMed: 28430547
Published Online: April 21, 2017

5. Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, **Nathan SD**, Wijsenbeek MS, Stauffer JL, Kirchgaessler K, Costabel U. Pirfenidone Safety and Adverse Event Management: Experience From Randomized Clinical Trials and Real-World Observations in Idiopathic Pulmonary Fibrosis. *European Respiratory Review* 2017;26:170057
6. **Nathan SD**, Martinez FJ. Pitfalls in developing new compounds for IPF. *Curr Opin Pulm Med* 2017, 23:426–431.
7. **Muhajan AK**, Folch E, **Khandhar SJ**, Channick CL, Santacruz JF, Mehta AC, **Nathan SD**. Airway complications following lung transplantation. *Chest*. 2017 Sep;152(3):627-638
8. **Brown AW**, **Nathan SD**. The Value and Application of the Six Minute Walk Test in Idiopathic Pulmonary Fibrosis. *Ann Am Thorac Soc*. 2017 Sep 21. doi: 10.1513/AnnalsATS.201703-244FR. [Epub ahead of print]
9. **King C**, Davis D, Dellgren G, Bekkers J, Mulligan MS, Van Raemdonck D, Gries C, Valentine V, Simon A. International Consensus Recommendations for Anaesthetic and Intensive Care Management of Lung Transplantation Surgical Complications
10. Benza R, Raina A, Kanwar MK, **Nathan SD**, Mathai SC. sGC stimulators: evidence in pulmonary hypertension and beyond. accepted to the *Journal of Rare Diseases Research and Treatment* 11/2/17.
11. **Nathan SD**. Evaluating New Treatment Options (for IPF): *Am J Managed Care* 2017;23:S139-146
12. **King CS**, **Roy A**, **Ryan L**, **Singh R**. Cardiac Support Emphasis of Venoarterial ECMO. *Crit Care Clin*. 2017; 33: 777-794.

BOOK CHAPTERS AND BOOKS

1. Understanding the Role of Comorbidities in Interstitial Lung Diseases. Shifren A, Russell T, Anderson A, **Nathan SD**. For *Clinical Handbook of Interstitial Lung Disease*, edited by Drs. Muhunthan Thillai, David R. Moller, and Keith C. Meyer. Published by CRC Press 2018
2. **King CS**, **Nathan SD**. Treatment of Pulmonary Hypertension in Interstitial Lung Disease. For *Pulmonary Hypertension and Interstitial lung disease*. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan. Published by Springer 2017
3. **Shlobin OA**, **Nathan SD**. Rare ILD and PH. For *Pulmonary Hypertension and Interstitial lung disease*. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan. Published by Springer 2017
4. **Nathan SD**, **Brown AW**, **King CS**. Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. Updated sales as of 1/23/2017: 400 copies and 1000 electronic downloads. **\$10,000 paid for royalties to the Inova Pulmonary Fibrosis fund** 😊

PRESENTATIONS AT NATIONAL/INTERNATIONAL MEETINGS

1. Keynote presentation: Advances in interstitial lung disease and IPF. VCU Health Advances in Pulmonary Disease conference. Richmond, VA 4/29/2017. (SN)
2. Pulmonary Hypertension in the setting of Lung Disease: Incidence, pathogenesis and Assessment. Annual Yale Pulmonary Hypertension conference. June 2nd, 2017 (SN)
3. Pulmonary Hypertension in Lung Disease: To tweet or not to tweet? Annual Yale Pulmonary Hypertension conference. June 2nd, 2017 (SN)
4. Uncommon Causes of Dyspnea: horses and zebras. Louisiana Academy of Family Physicians Annual meeting New Orleans, August 4th, 2017. (SN)
5. Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia.

- Podium presentation European Respiratory Society September 11th, 2017 Milan, Italy (SN)
6. Incidence of multiple progression events in patients with IPF in the pooled CAPACITY and ASCEND Phase III trials. Podium presentation European Respiratory Society September 12th, 2017 Milan, Italy (SN)
 7. Pulmonary Hypertension complicating Interstitial Lung Disease. World Association for Sarcoidosis and Other Granulomatous Disease annual meeting. Beijing, China October 21st, 2018. (SN)
 8. Treatment of Pulmonary Fibrosis. 1st Fellow Symposium on Advanced Lung Disease. American College of Chest Physicians meeting. Toronto Canada October 28th, 2017. (SN)
 9. Treatment of IPF in the era of antifibrotics. 2nd Annual Portuguese IPF meeting. Averoio, Portugal December 16th, 2017. (SN)

ORIGINAL RESEARCH ABSTRACTS & PRESENTATIONS TO INTERNATIONAL MEETINGS

ISHLT 2017

1. **Nayyar M, Shobin OA, King C, Fregoso MF, Verster A, Cochrane A, Nathan SD, Brown AW.** Outcomes of Recipients on Dual compared to Triple Immunosuppression after Lung Transplantation. ISHLT 2017
2. **Cho AH, Alhalabi L, Bernens M, Shlobin OA, King CS, Bogar L, Nathan SD, Brown AW.** Incidence and Impact of Gastroparesis Following Lung Transplantation. ISHLT 2017
3. **Franco-Palacios DJ, Brown AW, King C, Nunes FS, Mahajan A, Khandhar S, Venbrux A, Shlobin OA.** Post Lung Transplant Chylothorax Effectively Treated with Thoracic Duct Embolization. ISHLT 2017
4. S. M. Pham, S. Agbor-Enoh, I. Timofte, P. Shah, J. Orens, S. Gorham, K. Bhatti, A. Marishta, M. Yang, Y. Yang, U. Fideli, I. Tunc, J. Zhu, **S. Nathan, A. Brown**, A. Iacono, H. Valantine. Relationship Of Early Lung Allograft Injury As Measured By Cell Free DNA With Donor And Recipient Characteristics. ISHLT 2017 (12/21/2016)
5. Timofte I, Agbor-Enoh S, Iacono A, Orens J, Shah P, Gorham S, Bhatti K, Marishta A, Jang M, Yang Y, Fideli U, Tunc I, Zhu J, **Nathan SD, Brown AW**, Pham S, Valantine H. Severe Primary Graft Failure In a Lung Transplant Recipients That Required ECMO Had High Level Of Donor-Derived Cell-Free DNA. ISHLT 2017

ATS 2017

1. **Tsang AK, Shlobin OA, Weir N, King C, Brown AW, Nathan SD.** Do Lung function tests predict response to therapy in Connective Tissue Disease (CTD)-Associated Pulmonary Hypertension (PH)?
2. **Weir N, Brown AW, Della Santina J, King C, Lewis D, Nathan SD, Shlobin OA.** Transition from PDE-5 Inhibitors to Riociguat in Pulmonary Hypertension.
3. **S.R. Devarajan, B. Cannon**, S. Cousins, J. Maniaci, C. Roberts, C. Spaulding, P. Vaidya, **S.D. Nathan**. The Impact of Right Ventricular Diastolic Pressure on Mortality in Patients with Idiopathic Pulmonary Fibrosis.
4. **FS Nunes, AW Brown, OA Shlobin, E Battle, C. King, SD Nathan.** Mid-flow rates do not predict mortality in IPF patients.
5. **Alhalabi L, Cho AH, Shlobin OA, King C, Garofalo S, Lamberti J, Nathan SD, Brown AW.** Outcomes of Patients Requiring High Humidity High Flow Nasal Oxygen Cannula in a Tertiary Care Hospital.
6. **Kaur R, King CS, Brown AW, Ahmad S, Shlobin O, Weir N, Nathan SD.** Factors Affecting Selection

- of Anti-fibrotic Therapy in Idiopathic Pulmonary Fibrosis.
7. **Kaur R, King CS, Brown AW, Ahmad S, Shlobin O, Weir N, Nathan SD.** Real-World Tolerability of Anti-fibrotic Therapy for Idiopathic Pulmonary Fibrosis.
 8. **Jose A, King C, Nathan SD.** The Left and Right Ventricular End Diastolic Pressure Ratio As a Novel Marker of Disease Severity in a Cohort of Patients with Pulmonary Arterial Hypertension.
 9. **Jose A, King C, Nathan SD.** The Impact of Right Ventricular Diastolic Pressure on Mortality in Patients with Idiopathic Pulmonary Fibrosis
 10. **Welt E, Shlobin OA, King C, Weir N, Brown AW, Cossa N, Kiernan J, Nathan SD.** The role of exercise right heart catheterization in discerning heart failure with preserved ejection fraction.
 11. **Libre M, King CS, Brown AW; Ahmad S, Shlobin O, Weir N, Nathan SD.** Prevalence of Pulmonary Hypertension in Idiopathic NSIP and Effect of Pulmonary Vasodilator Therapy on Outcomes. Submitted to ATS 2017.
 12. **Siddiqui1 FM, King C, Bowen M, Fregoso M, Nathan SD, Brown AW.** Similar Outcomes of Lung Transplantation Using Increased Risk And Conventional Donor Lungs. Submitted to ATS 2017.
 13. **Nathan SD,** Costabel U, Albera C, Kirchgaessler KU, Chou W, Noble PW. Effect of Pirfenidone on All-Cause Mortality (ACM) and Forced Vital Capacity (FVC) in Idiopathic Pulmonary Fibrosis (IPF) Patients With Low FVC and/or Low DLCO: Analysis of Pooled Data From ASCEND and CAPACITY. Nathan SD, Macaula D, Garcia Horton V, Terasawa E, Yu YF. Patient characteristics, clinical outcomes and healthcare resource utilization among IPF patients stratified by lung function at diagnosis. Bui S, Tran L, Rodriguez L, Aljebur B, Nathan SD, Grant GM. Survival mechanisms for Idiopathic Pulmonary Fibrosis fibroblasts and the Unfolded Protein Response (UPR). Submitted to ATS 2017
 14. Gochuico BR, O'Brien KJ, **Nathan SD,** Goldberg HJ, Connors JM, Cui Y, Astor TL, Camp PC, Rosas IO, Lemma WoldeHanna M, Speransky V, Weinhouse GL, El-Chemaly S. Clinical Issues Associated With Lung Transplantation In Hermansky-Pudlak Syndrome Pulmonary Fibrosis. Submitted to ATS 2017
 15. Kaler M, Barochia AV, **Weir NA,** Cuento RA, Stylianou M, Roth MJ, Filie AC, **Vaughey EC, Nathan SD,** Levine SJ. A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of the PPAR-Agonist, Pioglitazone, for Severe Asthma. Submitted to ATS 2017
 16. A.M. Taveira-DaSilva, A. Jones, P. Julien-Williams, OA Shlobin, **SD Nathan,** J Moss. Recurrence of Lymphangioliomyomatosis After Double Lung Transplantation in a Patient With LAM. Submitted to ATS 2017
 17. Figueroa D, Bui S, Rodriguez L, Grant G, **Nathan SD,** Levine SJ. Apolipoprotein A-I and Apolipoprotein E Differentially Modulate the Expression of Extracellular Matrix Proteins by IPF Lung Fibroblasts. Submitted to ATS 2017
 18. Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Axmann J, Ireland L, **Nathan SD.** Differences in Patient and Physician Viewpoints of the Management of Idiopathic Pulmonary Fibrosis (IPF). Submitted to ATS 2017
 19. Mason WR, **Nathan SD,** Zibrak JD, Padilla ML, Gilberg F, Petzinger U, Kirchgaessler KU, Lancaster LH. Time-to-Event Analysis of Common Adverse Events of Pirfenidone in Patients With IPF—a Pooled Analysis of Three Phase III Clinical Trials.
 20. Rodriguez L, Aljebur B, Bui S, Tran L, **Nathan SD,** Grant G. Identification of a Subset of Rapidly Dividing and High Collagen Expressing Fibroblasts within a Heterozygous Cohort of Pulmonary Fibroblasts in Idiopathic Pulmonary Fibrosis. Submitted to ATS 2017
 21. S Braman, B Make, **J Lamberti, SD Nathan,** N MacIntyre, P Porte, G Criner. Acute Respiratory Failure

- That Develops During Hospitalization: A Comparison of Medical vs. Surgical Medicare Patients. Submitted to ATS 2017
22. **J Lamberti, SD Nathan**, N MacIntyre, S Braman, B Make, P Porte, GJ Criner. Medicare Patients Who Develop Respiratory Failure During Hospitalization have Higher Mortality Compared to Medicare Patients Admitted with Respiratory Failure. Submitted to ATS 2017
 23. Flaherty KR, de Andrade J, Chou W, Lancaster L, Lindell K, **Nathan SD**, Raghu G, Spino C, Staszak S, Stauffer JL, Tuomey P, Wolters PJ, Cosgrove GP. Baseline Characteristics of the initial 200 participants in the Pulmonary Fibrosis Foundation Registry.
 24. EH Alhamad, MB Scholand, DA Culver, **SD. Nathan**, E Carmona, V Kouranos, F Cordova, J Barney, M Wijnsenbeek, RP Baughman. Determinants Of Six Minute Walk Distance In Sarcoidosis Associated Pulmonary Hypertension. Submitted to ATS 2017
 25. Determinants of Health Related Quality of Life in PAH: Data from The Pulmonary Hypertension Association Registry. Roham Zamanian, David Badesch, Todd Bull, Teresa De Marco, Jeremy Feldman, Jeff Fineman, James Ford, Michael Grey, Dan Grinnan, James Klingler, John McConnell, Erika Berman Rosenzweig, Linda Santos, **Oksana Shlobin**, Jeff Sager on behalf of PHAR
 26. Characterization of Hispanics with pulmonary hypertension in the US: The Pulmonary Hypertension Association Registry V. De Jesus Perez, D. Badesch, R.T. Zamanian, J. Fineman, J.R. Klingler, J. Ford, J.W. McConnell, J. Sager, J. Feldman, **O. Shlobin**, D. Grinnan, T.M. Bull, E. Rosenzweig, L. Santos, T. DeMarco on behalf of PHAR
 27. TD Walker, J Powers, A Walts, JA de Andrade, E Bendstrup, TS Blackwell, R Borie, KK Brown, JD Christie, HR Collard, PJ Wolters, TJ Corte, B Crestanil, G Laurent, CM Prele, RM du Bois, T Maher, O Eickelberg, KF Gibson, D Kass, Y Zhang, M Henry, M Kennedy, G Gudmundsson, N Hirani, Y Inoue¹, R Braybrooke, RG Jenkins, M Keane, DS Kim, DJ Lederer, JE Loyd, N Mogulkoc, **S. Nathan**, I Noth, J Christie, M Porteous, K. Ohta, H Parfrey, C Ryerson, M Selman, JW Song, M. Sterclova, S Tomassetti, V Poletti, Martina Vasakova, MD Tobin, MI Schwarz, DA Schwartz. The global IPF Collaborative Network: A Platform for IPF Genetics. ATS 2017.

European Respiratory Society Sep 2017

1. Costabel U, Albera C, Wijnsenbeek MS, de Andrade JA, Mason WR, **Nathan SD**, Zibrak JD, Padilla ML, Gilberg F, Petzinger U, Kirchgaessler K, Lancaster LH. Characterization of fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled Phase III trials. ERS 2017
2. **Nathan SD**, Costabel U, Glaspole I, Glassberg MK, Lancaster LH, Lederer DJ, Pereira CA, Trzaskoma B, Limb S, Wells AU. Incidence of multiple progression events in patients with IPF in the pooled CAPACITY and ASCEND Phase III trials. ERS 2017
3. **Nathan SD**, Behr J, Collard HR, Cottin V, Hoepfer MH, Martinez F, Corte T, Keogh A, Leuchte H, Moğolkoc N, Ulrich-Somaini S, Wuyts W, Malcolm S, DiCasoli C, Yao M, Athol Wells AU. RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia. Submitted to ERS 2017

Chest 2017

1. **Cho AH, Alhalabi L**, Bernens M, **Shlobin OA, King CS, Bogar L, Nathan SD, Brown AW**. Incidence and Impact of Gastroparesis Following Lung Transplantation. To be submitted to Chest 2017
2. Warren WA, **Franco-Palacios D, King CS, Shlobin OA, Nathan SD, Katugaha S, Mani H, Brown AW**. Opportunistic Infection by a Very Unusual Fungus in a Cystic Fibrosis Patient. To be submitted to Chest 2017.

3. Ratwani A, **King CS, Brown AW, Shlobin OA, Weir N, Nathan SD**. Tracheobronchial tree size as a predictor of disease severity and outcomes in Idiopathic Pulmonary Fibrosis. To be submitted to Chest.
4. **Nunes FS, Alhalabi L, Brown AW, Shlobin OA, King C, Nathan SD**. Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis? Submitted to Chest 2017.
5. Patrick Kicker D.J. **Franco-Palacios, O.A. Shlobin, Q. Zhao, M. Gomberg-Maitland**, Sildenafil for this HFpEF?: Diastolic dysfunction and Gerbode defect induced combined pre and post-capillary pulmonary hypertension.